The health biotech industry is buzzing with investor focus shifting towards the valuation of **Amgen (AMGN)**. This follows a 4.6% pullback in share price, which earned it a buy rating from Wall Street Zen and increased price targets by Wells Fargo and Cantor Fitzgerald. The company produced strong results from its **TEPEZZA** and **MariTide** trials, enhancing their profitability potential and drawing a bullish stance from billionaire Ken Fisher. Its approach to the obesity strategy and GLP-1 therapies via collaboration with Ro has impressed the market. Notable share sales by Clarity Wealth Advisors LLC and Encompass Wealth Advisors LLC are balanced by significant holdings by Prime Capital Investment Advisors LLC and KFG Wealth Management LLC. **Amgen's** Tarlatamab has gained approval in China and shows promise in the lung cancer realm. The company's latest Q4 earnings beat estimates, despite some concerns about share price overvaluation and mixed returns. Amgen has also shown a commitment to lowering medication costs with new initiatives like TrumpRx Discounts. Bernstein is cautiously optimistic, dubbing 2026 a “Waiting Year” for MariTide, while HSBC is increasingly bullish about Amgen's prospects moving into 2026.
Amgen AMGN News Analytics from Wed, 15 Oct 2025 07:00:00 GMT to Sat, 11 Apr 2026 22:17:06 GMT -
Rating 7
- Innovation 8
- Information 9
- Rumor -2
